Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$196.3M
3M shares
52-week range
$23.47 – $68.99
77% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.5M | $27.2M | $34.8M | $42.0M | $42.0M | $46.1M | $53.8M | $66.6M |
| Cost of revenue | $14.5M | $17.4M | $21.7M | $28.9M | $28.9M | $33.3M | $39.3M | $47.1M |
| Gross profit | $7.9M | $9.8M | $13.1M | $13.1M | $13.1M | $12.7M | $14.6M | $19.5M |
| Gross margin | 35.4% | 36.0% | 37.7% | 31.2% | 31.2% | 27.7% | 27.0% | 29.3% |
| R&D | $1.9M | $1.9M | $2.3M | $3.0M | $3.0M | $2.8M | $3.2M | $3.6M |
| Operating income | $2.4M | $5.0M | $7.1M | $5.1M | $5.1M | $5.8M | $7.2M | $10.7M |
| EBITDA | $4.0M | $5.4M | $8.8M | $6.9M | $6.9M | $10.8M | $4.4M | $14.1M |
| Net income | $1.6M | $4.1M | $6.1M | $4.6M | $4.6M | $7.1M | $2.1M | $9.0M |
| Net margin | 7.2% | 15.3% | 17.5% | 10.9% | 10.9% | 15.3% | 4.0% | 13.5% |
| EPS (diluted) | 0.37 | 0.97 | 1.50 | 1.13 | 1.21 | 1.95 | 0.60 | 2.67 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $76M | $3.94 | $3.94–$3.94 | 1 |
| 2027 | $81M | $2.78 | $2.78–$2.78 | 1 |
Forward consensus · source: Financial Modeling Prep
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
www.pro-dex.comNo one on the platform currently holds PDEX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 11,240 | $490.5K |
| Execution date | Ratio |
|---|---|
| 2010-06-18 | 1-for-3reverse |
No one on the platform has traded PDEX yet.
| $43M |
| — |
| LUCDLucid Diagnostics Inc. | $1.05 | -2.78% | $107M | — |
| MBOTMicrobot Medical Inc. | $1.87 | +5.65% | $85M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PDEX Excellent article that nails exactly where PDEX stands right now. So if you want to update your PDEX knowledge or get acquainted with PDEX, this is a must read. https://everyticker.com/quote/PDEX/analysis/pro-dex-a-surgical-device-turnaround-meets-customer-concentration-reality-nasdaq-pdex
View on StockTwits ↗Fundamental analysis of $PDEX (PRO DEX INC) based on financial data and reported results. #PDEX
View on StockTwits ↗$PDEX chop chop huckleberries and a 🧠 return on the DLO. 🐒🍌🧠⏰♾️
View on StockTwits ↗$PDEX Pro-Dex manufactures medical device components. Revenue depends on customer concentration. Margins fluctuate with volume.
View on StockTwits ↗$PDEX Decision quality at the top will shape trajectory, while management calibrates resource allocation to real demand signals. Proof points carry more weight than guidance alone.
View on StockTwits ↗$PDEX Current positioning will be tested as external catalysts materialize before balance-sheet pressure intensifies. Execution slippage remains the dominant downside risk.
View on StockTwits ↗$PDEX (+4.7% pre) PRO-DEX, INC. ANNOUNCES CONTRACT EXTENSION WITH LARGEST CUSTOMER https://ooc.bz/l/88143
View on StockTwits ↗$PDEX +5.32 Pro-Dex announced fiscal Q1 2026 results today, reporting a 24% year-over-year increase in net sales to $18.5 million and net income of $4.7 million, boosted by resumed shipments to its largest customer and gains from an investment acquisition.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 20.9× earnings vs its 15.7× historical median P/E.
Fair value ≈ $44.07 · price $58.40 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.